- Home
- BDTX vs SILC Comparison
BDTX vs SILC Comparison
Compare BDTX & SILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | SILC |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 163.8M |
| IPO Year | 2020 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BDTX | SILC |
|---|---|---|
| Price | $1.76 | $46.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 143.0K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $12.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.78 | $13.34 |
| 52 Week High | $4.94 | $52.58 |
Technical Indicators
Market Signals| Indicator | BDTX | SILC |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 59.05 |
| Support Level | N/A | $16.31 |
| Resistance Level | $2.30 | $50.75 |
| Average True Range (ATR) | 0.14 | 4.64 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 5.41 | 81.20 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.